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To the Editor:
A female infant (age, 2 years and 4 months) 
from the city of São Paulo, Brazil, had been 
vaccinated with BCG in the maternity ward and 
presented with a 15-day history of pain in the 
right leg and impaired ambulation. The patient 
was treated with a nonsteroidal anti-inflammatory 
drug and showed improvement. However, two 
weeks after the drug had been discontinued, 
she showed worsening. An X-ray of the knee 
showed an osteolytic lesion in the right distal 
femoral epiphysis. Magnetic resonance imaging 
(Figure 1) revealed a centromedial lesion in the 
right distal femoral epiphysis, with multiple areas 
of cortical erosion; there was significant cortical 
discontinuity, and there was no effusion in the 
posteroinferior portion of the medial femoral 
condyle. The patient was treated with ceftriaxone 
for 14 days, with no improvement. A punch 
biopsy of the right knee showed a granuloma 
with no AFB. The patient was started on isoniazid, 
rifampin, and pyrazinamide. Investigation of her 
parents, siblings, and nannies showed no exposure 
to pulmonary or extrapulmonary tuberculosis. 
At admission to our facility, a few days after 
treatment initiation, the patient was in good 
general health. The only abnormality on physical 
examination was right knee edema (distal and 
proximal to the tibia). The edema was cold and 
painful on palpation, being accompanied by 
functional disability.
The following tests were performed: tuberculin 
skin testing with PPD, the induration being 14 
mm; X-ray and magnetic resonance imaging 
of the right knee; enzyme-linked immunospot 
(ELISPOT) assay, the results being negative; knee 
biopsy, revealing very little bone tissue with 
two epithelioid granulomas (one of which had 
caseous necrosis) and chronic lymphoplasmacytic 
inflammatory infiltrate; AFB testing, the results 
being negative; mycobacterial culture, the results 
being positive; PCR testing, revealing the presence 
of insertion sequence 6110 (which is characteristic 
of mycobacteria) and duplication of spacer 33 
in the DR region (172-bp amplicon), present 
only in the Mycobacterium bovis BCG strain 
and absent in M. tuberculosis; PCR testing, the 
results being negative for M. tuberculosis; routine 
tests (complete blood count, ESR determination, 
HIV testing, and evaluation of liver and kidney 
function), the results being normal; humoral 
and cellular immune response testing, the results 
being normal (Table 1); and chest CT, the findings 
being normal.
The patient achieved a satisfactory clinical 
improvement and was discharged after 18 months 
of treatment, at which point an X-ray of the 
right femur showed normal findings.
The BCG vaccine is used in many countries, 
and there are no strict rules regarding the age of 
vaccination, the groups that should be vaccinated, 
the type of vaccine, the concentration of bacilli, 
the ratio of live to dead bacilli, or the mode of 
administration. Many strains are used; however, 
there is uncertainty regarding the total number 
of viable and nonviable bacilli (which could 
potentiate the immunity induced by the former) 
and the ability of PPD to induce allergy, both 
of which are factors that can have an impact on 
the potency and complications of the vaccine.
(1,2) In Brazil, vaccination with BCG Moreau is 
given intradermally (at the insertion of the right 
deltoid) in the first days of life, at concentrations 
of 300,000-1,000,000 bacilli/dose.
Severe side effects are rare and include 
persistent ulceration at the vaccination 
site, surrounding adenopathy, osteitis, and 
disseminated disease, which can occur in severely 
immunocompromised individuals (including the 
cases of locally administered vaccine in patients 
with bladder carcinoma). In the Czech Republic, 
the incidence of complications has decreased 
with the use of lower doses of the vaccine.(3)
Letter to the Editor
Osteitis in a female infant after vaccination with BCG Moreau in the neonatal period
J Bras Pneumol. 2012;38(5):674-676
675
immunocompetent child who presented with 
radial and ulnar lesions and who was highly 
suspected of having BCG osteitis, although the 
bacillus was not identified.(8)
The diagnosis of BCG osteitis in our patient is 
indisputable. Tuberculin skin testing confirmed that 
PPD positivity does not depend on M. tuberculosis, 
given that ELISPOT assay results were negative. 
Biopsy showed a caseating granuloma, no bacilli 
having been identified. However, culture was 
positive, confirming mycobacteriosis. The presence 
of BCG was confirmed by PCR revealing insertion 
sequence IS6110, which is characteristic of the 
vaccine. Therefore, this seems to be the first 
confirmed case of osteitis after vaccination with 
BCG Moreau. The classic criteria of Foucard & 
Hjelmstedt(9) are useful in raising the suspicion of 
BCG osteitis, because they include vaccination in 
the neonatal period, development of symptomatic 
disease up to four years after vaccination, no 
contact with tuberculosis, a clinical profile 
consistent with tuberculosis, and histopathological 
findings consistent with tuberculosis. Our patient 
met those criteria. However, the current gold 
standard is the detection of the presence of 
M. bovis.
The patient was treated with isoniazid, rifampin, 
and pyrazinamide because of the presumptive 
diagnosis of tuberculosis. The hypothesis of 
osteitis after BCG vaccination was raised later, 
pyrazinamide being discontinued because BCG 
is resistant to the drug. The treatment continued 
for 18 months, and complete cure was achieved. 
However, treatment with only isoniazid and 
rifampin for 6 months has been reported to be 
successful. Recurrence is rare.
Osteitis after BCG vaccination is slightly 
more common in boys than in girls. Humeral 
osteitis results from contiguous spread, which 
In Russia, the incidence of bone tuberculosis 
has been reported to be higher than that of 
primary tuberculosis, BCG having been confirmed 
as the cause of osteitis in 46% of the patients 
who presented with the disease.(4)
In Japan, the incidence of osteitis has been 
reported to be 0.2 cases/100,000 vaccinations, 
varying according to the BCG strain(5) and the 
use of vaccines that are less reactogenic.(6) In 
Finland, the incidence of osteitis has also been 
reported to vary according to the BCG strain.(7)
We found no reports of osteitis caused 
by BCG Moreau. However, it should be noted 
that BCG Moreau is not as widely used as are 
other strains, particularly BCG Glaxo and BCG 
Pasteur-Paris. In Brazil, one group of authors(8) 
recently reported the case of a normal-weight, 
Figure 1 - Magnetic resonance imaging of the right 
femur showing osteolytic lesions.
Table 1 - Immune status of the patient.
Test Result
Determination of antibodies against rubella, measles, and 
pneumococci
Normal
Dihydrorhodamine oxidation test 241 units (reference value, > 80 units)
Total lymphocyte count 5,880 cells/mm3 
Total T lymphocyte count 3,587 cells/mm3 (61%; reference value, 64%)
CD4 count 37%
CD8 count 24%
Natural killer lymphocyte count 5,849 cells/mm3 (13%)
CD56/16 CD3 count 781 (14%; normal range, 6-29%)
Note: BCG was isolated in the Clinical Laboratory of the Hospital Israelita Albert Einstein, in the city of São Paulo, 
Brazil, as described by Yeboah-Manu D et al.(14)
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was impossible in our patient. Osteitis resulting 
from hematogenous spread is more likely, occurring 
primarily in the epiphyses of long bones in the 
arms and legs (which are highly vascularized) and 
being usually solitary.(5,10) Involvement of other 
bones, such as the sternum(11) and the sacrum,(12) 
is extremely rare. The unilaterality of the disease 
suggests that circulation was increased (by minimal 
trauma, for instance) prior to the onset of the 
bacilli. However, it is strange that other highly 
vascularized organs are more resistant.
Dissemination of BCG is facilitated by 
immunosuppression, which was not observed 
in our patient. She had a normal complete blood 
count and normal counts of lymphocytes, CD4, 
CD8, and natural killer lymphocytes, as well as 
having normal levels of antibodies against rubella, 
measles, and pneumococci. In addition, she had 
a normal dihydrorhodamine oxidation test result. 
Unfortunately, it was impossible to determine 
IL-12 levels, and deficiency/absence of IL-12 
might be related to mycobacterial disease. In 
Brazil, this condition was found in two brothers 
with BCG adenitis and deficient IL-12 production 
after stimulation with INF-γ.(13)
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